PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
- 1 February 1997
- journal article
- Published by Elsevier in The Lancet
- Vol. 349 (9049), 385-388
- https://doi.org/10.1016/s0140-6736(97)80010-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary ThrombosisNew England Journal of Medicine, 1996
- Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic StrategyCirculation, 1995
- Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular MedicineNew England Journal of Medicine, 1995
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- Nomenclature of platelet‐specific antigensTransfusion, 1990
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.Journal of Clinical Investigation, 1989